Cencora, Inc.
331.00USD
-7.4800 (-2.21%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on COR.
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 238.6B | 262.2B | 294.0B | 321.3B | 337.0B | 351.7B |
| Q1 | 59.6B | 62.8B | 72.3B | 81.5B | 85.9B | 90.0B |
| Q2 | 57.7B | 63.5B | 68.4B | 75.5B | 78.4B | — |
| Q3 | 60.1B | 66.9B | 74.2B | 80.7B | 84.8B | — |
| Q4 | 61.2B* | 68.9B* | 79.1B* | 83.7B* | 87.9B | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 8.04 | 8.53 | 7.53 | 7.96 | 17.88 | 19.76 |
| Q1 | 2.13 | 2.33 | 2.98 | 2.50 | 2.87 | 4.58 |
| Q2 | 2.59 | 2.13 | 2.09 | 3.68 | 8.40 | — |
| Q3 | 1.92 | 2.35 | 2.42 | 3.52 | 3.94 | — |
| Q4 | 1.40* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| 1.71* |
| .017* |
| -1.74* |
| 4.57 |
| — |
Debt level and coverage